Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model

@inproceedings{ArlandisGuzmn2011CosteffectivenessAO,
  title={Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model},
  author={Salvador Arlandis-Guzm{\'a}n and Carlos Errando-Smet and Jeffrey N Trocio and Daniel Arum{\'i} and Javier Rejas},
  booktitle={BMC urology},
  year={2011}
}
BACKGROUND Fesoterodine, a new once daily antimuscarinic, has proven to be an effective, safe, and well-tolerated treatment in patients with overactive bladder (OAB). To date, no analysis has evaluated the economic costs and benefits associated with fesoterodine, compared to antimuscarinics in Spain. The purpose of this analysis was to assess the economic value of OAB treatment with fesoterodine relative to extended release tolterodine and solifenacin, from the societal perspective. METHODS… CONTINUE READING
13 Citations
53 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Impacto de la morbilidad, uso de recursos y costes en el mantenimiento de la remisión de la depresión mayor en España: estudio longitudinal de ámbito poblacional

  • A Sicras-Mainar, M Blanca-Tamayo, L Gutiérrez-Nicuesa, J Salvatella-Pasant, R Navarro-Artieda
  • Gac Sanit
  • 2010
1 Excerpt

eSALUD

  • Oblikue
  • Base de datos de costes sanitarios.Edited by…
  • 2010

Similar Papers

Loading similar papers…